Compare JLL & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JLL | VTRS |
|---|---|---|
| Founded | 1997 | 1961 |
| Country | United States | United States |
| Employees | 48000 | 30000 |
| Industry | Real Estate | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3B | 18.7B |
| IPO Year | 1997 | 2019 |
| Metric | JLL | VTRS |
|---|---|---|
| Price | $343.55 | $16.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $365.33 | $13.50 |
| AVG Volume (30 Days) | 283.3K | ★ 6.7M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | ★ 45.13 | N/A |
| EPS | ★ 7.91 | 0.05 |
| Revenue | ★ $26,115,600,000.00 | $14,299,900,000.00 |
| Revenue This Year | $7.71 | $4.41 |
| Revenue Next Year | $6.99 | $1.96 |
| P/E Ratio | ★ $43.86 | $330.20 |
| Revenue Growth | ★ 11.45 | N/A |
| 52 Week Low | $259.83 | $9.43 |
| 52 Week High | $393.84 | $18.39 |
| Indicator | JLL | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 50.70 |
| Support Level | $334.29 | $15.89 |
| Resistance Level | $359.64 | $17.22 |
| Average True Range (ATR) | 9.93 | 0.39 |
| MACD | -4.40 | 0.00 |
| Stochastic Oscillator | 20.07 | 47.41 |
Jones Lang LaSalle is a global commercial real estate services and investment management company that helps clients buy, build, occupy, manage, and invest in property across office, industrial, retail, multifamily, hotel, and data center assets. For over 200 years, clients have trusted JLL, a Fortune 500 company, tracing its roots to firms including LaSalle Partners (founded in Chicago in 1968) and the centuries-old London firm Jones Lang Wootton, which merged in 1999 to form the modern JLL. Today the firm is a leading global commercial real estate services and investment management company with operations in over 80 countries, and a global workforce of more than 113,000, as of early 2026.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.